Scarica l'app Stockscreener
3.215
4.04%
-0.125
Precedente Chiudi:
$3.34
Aprire:
$3.32
Volume 24 ore:
347.60K
Relative Volume:
0.05
Capitalizzazione di mercato:
$297.66M
Reddito:
-
Utile/perdita netta:
$-69.31M
Rapporto P/E:
-2.5315
EPS:
-1.27
Flusso di cassa netto:
$-62.80M
1 W Prestazione:
-5.18%
1M Prestazione:
+48.04%
6M Prestazione:
-45.40%
1 anno Prestazione:
-38.95%
Intervallo 1D:
$3.17
$3.32
Intervallo di 1 settimana:
$3.1501
$3.59
Portata 52W:
$1.07
$11.46
Rezolute Inc Stock (RZLT) Company Profile
Nome
Rezolute Inc
Settore
Industria
Telefono
650-206-4507
Indirizzo
275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY
Confronta RZLT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RZLT
Rezolute Inc
|
3.21 | 309.71M | 0 | -69.31M | -62.80M | -1.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.69 | 119.22B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
762.00 | 77.93B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
844.77 | 52.01B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
337.86 | 44.66B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.72 | 37.67B | 4.98B | 69.60M | 525.67M | 0.5198 |
Rezolute Inc Stock (RZLT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-11 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-12-11 | Downgrade | Craig Hallum | Buy → Hold |
| 2025-12-11 | Downgrade | Wedbush | Outperform → Neutral |
| 2024-11-05 | Iniziato | Wedbush | Outperform |
| 2024-08-27 | Iniziato | Guggenheim | Buy |
| 2024-07-17 | Iniziato | BTIG Research | Buy |
| 2024-06-04 | Iniziato | Craig Hallum | Buy |
| 2024-04-09 | Iniziato | Maxim Group | Buy |
| 2022-08-02 | Ripresa | Canaccord Genuity | Buy |
| 2022-06-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-09-08 | Iniziato | ROTH Capital | Buy |
| 2021-05-27 | Iniziato | Oppenheimer | Outperform |
| 2021-05-25 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Rezolute Inc Borsa (RZLT) Ultime notizie
Rezolute, Inc. (NASDAQ:RZLT) Sees Significant Increase in Short Interest - MarketBeat
Rezolute, Inc. (NASDAQ:RZLT) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Rezolute (NASDAQ:RZLT) Shares Down 3.8%What's Next? - MarketBeat
SHAREHOLDER INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - Prime Publishers, Inc.
Analysis Recap: Will Rezolute Inc benefit from rate cutsJuly 2025 Volume & Low Volatility Stock Recommendations - baoquankhu1.vn
Rezolute shares in focus after RA Capital discloses 9.9% stake - MSN
Faruqi & Faruqi Encourages Rezolute Investors to Discuss Legal Options - Intellectia AI
INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - PR Newswire
RZLT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - FinancialContent
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rezolute, Inc.RZLT - PR Newswire
INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - GlobeNewswire Inc.
Trading Recap: Is Rezolute Inc a top pick in the sectorPortfolio Gains Summary & Safe Swing Trade Setups - baoquankhu1.vn
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - The Malaysian Reserve
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Beha - GuruFocus
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - TMX Newsfile
Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating - Sahm
FMR LLC Significantly Reduces Holdings in Rezolute Inc. - GuruFocus
Entry Recap: Is Rezolute Inc a top pick in the sectorMarket Activity Summary & Precise Swing Trade Alerts - baoquankhu1.vn
RZLT INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - Chartmill
RZLT ALERT: Levi & Korsinsky Investigates Rezolute, Inc. for Possible Securities Fraud Violations - marketscreener.com
RZLT Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - marketscreener.com
When the placebo isn’t inert: Rezolute’s CEO on the 40% response rate that upended a phase 3 trial - drugdiscoverytrends.com
Rezolute Downgrade Brings Investor Caution Amid Study Challenges - StocksToTrade
Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - MarketScreener
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - TMX Newsfile
Is Rezolute Inc. stock positioned well for digital economyJuly 2025 Big Picture & Daily Volume Surge Signals - ulpravda.ru
Rezolute Updates sunRIZE Phase 3 Trial and FDA Plans - TipRanks
Did You Suffer Losses in Rezolute, Inc. (RZLT)? Contact Levi & Korsinsky About Securities Fraud Claims - ACCESS Newswire
Does Rezolute Inc. stock trade at a discount to peersAnalyst Upgrade & Long-Term Safe Return Strategies - ulpravda.ru
Will Rezolute Inc. (6HV1) stock test record highs in 2025Market Activity Report & Fast Entry Momentum Alerts - ulpravda.ru
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - Bluefield Daily Telegraph
Rezolute (RZLT): Wedbush Analyst Raises Price Target to $2.00 | - GuruFocus
Why analysts upgrade Rezolute Inc. stockJuly 2025 Macro Moves & Free Fast Entry Momentum Trade Alerts - ulpravda.ru
Rezolute (NASDAQ:RZLT) Given Buy Rating at BTIG Research - MarketBeat
Jefferies reiterates Buy rating on Rezolute stock, maintains $4 target By Investing.com - Investing.com Canada
Wedbush Doubles Price Target on Rezolute to $2 From $1, Keeps Neutral Rating - marketscreener.com
BTIG Reiterates Buy Rating for Rezolute (RZLT) with $5 Target Pr - GuruFocus
Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism - StreetInsider
Jefferies reiterates Buy rating on Rezolute stock, maintains $4 target - Investing.com
Rezolute Hopes To Find A Way Forward In Congenital HI After Phase III Miss - Citeline News & Insights
Rezolute (RZLT) Shows Promising Results in Hypoglycemia Treatmen - GuruFocus
Can Rezolute's SunRIZE Study, Tumor HI Data Redefine Treatment For Hyperinsulinism? - Nasdaq
Rezolute (RZLT) Analyzes Phase 3 sunRIZE Study Outcomes - GuruFocus
Rezolute shares mixed results from Phase 3 trial for rare disease therapy - Investing.com Nigeria
Rezolute shares mixed results from Phase 3 trial for rare disease therapy By Investing.com - Investing.com South Africa
Rezolute rises as drug shows promise for rare low blood sugar disorders - TradingView — Track All Markets
Rezolute, Inc. Shares Findings on Ersodetug's Efficacy for Congenital and Tumor Hyperinsulinism, Plans FDA Meeting to Discuss Path Forward - Quiver Quantitative
Rezolute Inc Azioni (RZLT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Rezolute Inc Azioni (RZLT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ROBERTS BRIAN KENNETH | Chief Medical Officer |
Dec 16 '25 |
Buy |
1.70 |
28,000 |
47,600 |
308,352 |
| Evans Daron | CFO |
Dec 15 '25 |
Buy |
1.77 |
40,000 |
70,640 |
415,900 |
| Evans Daron | CFO |
Dec 15 '25 |
Buy |
1.79 |
5,000 |
8,938 |
7,000 |
| Elam Nevan C | CEO |
Dec 15 '25 |
Buy |
1.59 |
32,000 |
50,880 |
641,119 |
| Karnawat Sunil Ratilal | Chief Commercial Officer |
Dec 15 '25 |
Buy |
1.62 |
12,100 |
19,599 |
71,542 |
| ROBERTS BRIAN KENNETH | Chief Medical Officer |
Jun 25 '25 |
Buy |
4.38 |
2,500 |
10,939 |
15,500 |
| Evans Daron | CFO |
Jun 24 '25 |
Buy |
4.05 |
5,000 |
20,250 |
268,900 |
| Kim Young-Jin | Director |
Jun 13 '25 |
Buy |
3.25 |
1,230,769 |
3,999,999 |
8,423,386 |
| KREHER NERISSA | Director |
Jun 13 '25 |
Buy |
3.25 |
3,076 |
9,997 |
37,576 |
| Hogenhuis Wladimir | Director |
Mar 31 '25 |
Buy |
2.92 |
6,758 |
19,733 |
84,025 |
0.26%
1.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):